Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
The hour's business headlines, with CNBC's Mike Huckman.
A look at the latest drug development news, with CNBC's Mike Huckman and Les Funtleyder, Miller Tabak healthcare strateg...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

PHARMA'S MARKET VIDEO

» More

Current DateTime: 05:08:43 05 Jul 2009
LinksList Documentid: 31171988
Expiration DateTime: 7/5/2009 5:09:08 PM

RSS FEED

» Help

Current DateTime: 05:08:44 05 Jul 2009
LinksList Documentid: 31171995
Pharma's Market Blog
Text Size
Jun.10
1:28 PM ET

Shares of Amylin are ambling higher today after two destructive trading days.

First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.

So, today the shoe's on the other foot for NVO [NVO  Loading...      ()   ]. You can hear what AMLN CEO Dan Bradbury thinks of Novo's Friday press release in the video clip below, from his "First on CNBC" interview on "Squawk on the Street" this morning.

The stocks have changed direction after Amylin [AMLN  Loading...      ()   ], Eli Lilly [LLY  Loading...      ()   ] and Alkermes [ALKS  Loading...      ()   ]  announced that after one year patients on once-a-week Byetta saw a key measure of their blood sugar level drop two percentage points and their weight go down nearly 10 pounds.

FBR biotech analyst Jim Reddoch calls the results "unprecedented." David Kliff of the "Diabetic Investor" newsletter says, ""Quite frankly the results...aren't great they're astonishing." Rodman & Renshaw's Mike King in a research note to clients writes that they're "incredibly consistent results."

But Swiss drugmaker Roche also announced test results here on a similar once-a-week product. Wachovia analyst George Farmer says Roche's drug, which is moving into late-stage studies, "emerges as a strong competitor."

Combined with Novo's test results on a one-a-day version of the same class of drug Farmer says, "We see credible competition to AMLN's (Byetta) franchise beginning to emerge by 2010."

Wachovia, FBR and R&R make a market in AMLN. FBR would also like to bank the company.

In his wrap-up ADA meeting note to subscribers today Kliff concludes, "In this heavyweight fight Novo threw everything they had at Amylin who was able to withstand the assault. In the end investors should thank the people at Novo for creating a great entry point into Amylin shares. While a bit bloody after a tough few days, Amylin remains the most valuable property in the diabetes space."

Who knew bloody fights could break out at scientific meetings?

Actos Booth
To the right of Mike is HDL or "good" cholesterol. To his left in green is a triglyceride. The photo was taken at the booth for the diabetes drug Actos on the exhibit floor at the ADA meeting at Moscone Center in San Francisco.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post


Current DateTime: 01:01:23 05 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:01:22 05 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 01:01:22 05 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:01:22 05 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters